We are Abzena. More than a CDMO, we are a responsible and dedicated Partner Research Organization (PRO) that takes care of your products from concept to patient. With extensive experience in developing biologics and bioconjugates, we offer a seamless service delivered by fully integrated teams, from early discovery to commercial manufacturing. Forward-thinking and committed, we find the best solution and use the right technologies to design, develop and manufacture your products to ensure we get vital medicines to patients quickly and safely. We are dedicated to quality excellence. We are driven to get better treatments to market, efficiently and responsibly by reducing timelines and delivering the highest quality products and services.
BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxic characteristics for the pharmaceuticals industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.
Goodwin Biotechnology’s mission is to eliminate the manufacturing risk for companies developing complex biologic therapeutics by being the pre-eminent provider of high-quality, cost-effective, flexible and timely cGMP compliant manufacturing solutions, from pre-clinical development through commercial product supply. By integrating our services in one location, Goodwin provides a Single Source Solution™ to anticipate and overcome the challenges you face with your biopharmaceutical candidate, whether it be complex proteins such as monoclonal antibodies or a sophisticated Antibody Drug Conjugate (ADC).
Quanta BioDesign’s dPEG® platform is founded upon discrete MW PEGs, which enable assembly of unique structures with single-molecule precision and without the liabilities associated with hydrophobic carbon-based linkers. Broadly speaking, ADCs combine an antibody’s antigen-targeting properties with a payload’s cell-killing properties. The dPEG® product line facilitates linker architectures that enhance a conjugate’s tumor-targeting properties by altering its physicochemistry, pharmacokinetics, and biodistribution (See
Chemical Linkers in Antibody Drug Conjugates, Royal Society of Chemistry, 2021). Tailoring these properties, through the optimal incorporation of dPEG® components, to shift in vivo delivery from off-target to tumor-targeted pathways has the potential to improve therapeutic margins.
Singzyme’s mission is to deliver on the promise of effective mmune-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide. Singzyme applies its platform technology in the field of mmune-therapies with a focus on the conjugation of active molecules to protein carriers, for example, but not limited to Antibody-Drug Conjugates (ADCs).
SpectronRx teams are proven experts in monoclonal antibody labeling, with a variety of isotopes. We are a logistics champion of import/export, and a top-tier expert in world procurement of isotopes. We are your experienced early-stage to commercialization contract developer with a global and domestic respected outreach in radiotherapy. The varied and experienced SpectronRx team bring you the excellence needed for rapid advancement towards key milestones and increased demand for early phase therapeutic and diagnostic development services. SpectronRx can be your END-to-END solution for ALL critical phases of drug development, now or scalable to your budget and timeline